LGVN

Longeveron

LGVN

Market cap $16.4M

Overview Fund Activity

0.7876 USD

-0.0074

0.93%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.7899

+0.0023

0.29%

1 day

-0.93%

5 days

-0.3%

1 month

15.74%

3 months

-40.33%

6 months

-53.67%

Year to date

-56%

1 year

-61.01%

5 years

-98.94%

10 years

-98.94%

About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Employees: 25

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

20% more funds holding

Funds holding: 20 [Q1] → 24 (+4) [Q2]

10% more capital invested

Capital invested by funds: $791K [Q1] → $869K (+$78.3K) [Q2]

1.15% more ownership

Funds ownership: 3.78% [Q1] → 4.93% (+1.15%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$3

281% upside

Avg. target

$3

281% upside

High target

$3

281% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Roth Capital

Boobalan Pachaiyappan

$3

Buy

Maintained

15 Aug 2025

See Analyst Rankings

Financial journalist opinion

Longeveron® Announces Key Leadership Updates

Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors Wa'el Hashad to step down as CEO and Board member National search to occur for permanent CEO MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced key leadership updates.

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Joshua Michael Hare - Co-Founder, Chief Science Officer & Chairman Lisa A. Locklear - CFO, Executive VP & Treasurer Mohamed Wa'el Ahmed Hashad - CEO & Director Nataliya Agafonova - Chief Medical Officer Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners, LLC, Research Division Michael Okunewitch - Maxim Group LLC, Research Division Raghuram Selvaraju - H.C.

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2025 and provided a business update.

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the closing of its previously announced public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants have an exercise price of $0.85 per share and are immediately exercisable upon issuance for a period of twenty-four months following the date of issuance.

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have an exercise price of $0.85 per share and will be immediately exercisable upon issuance for a period of twenty-four months following the date of issuance.

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m.

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron has licensed issued US Patent 12,168,028 B2 , entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs) New technology substantially advances Longeveron's repertoire of stem cell therapy technologies Opportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that it has licensed an issued US patent (12,168,028 B2) for a stem cell technology from the University of Miami. The composition of matter patent protects unique induced pluripotent derived cardiomyogenic cells that have widespread therapeutic indications for heart diseases.

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program.

Longeveron® Appoints Than Powell as Chief Business Officer

See News Rankings

Charts implemented using Lightweight Charts™